Diseases [C] » Digestive System Diseases [C06] » Gastrointestinal Diseases » Intestinal Diseases
Hierarchy View
Subtype Terms (25)
Colonic Diseases
40 drugs (25 approved, 15 experimental)
Duodenal Diseases
1 experimental drug
Dysentery
11 drugs (7 approved, 4 experimental)
Enteritis
15 drugs (4 approved, 11 experimental)
Enterocolitis
9 drugs (6 approved, 3 experimental)
HIV Enteropathy
1 approved drug
Inflammatory Bowel Diseases
171 drugs (91 approved, 80 experimental)
Intestinal Atresia
3 drugs (2 approved, 1 experimental)
Intestinal Diseases, Parasitic
2 approved drugs
Intestinal Failure
6 drugs (1 approved, 5 experimental)
Intestinal Fistula
6 drugs (2 approved, 4 experimental)
Intestinal Neoplasms
467 drugs (237 approved, 230 experimental)
Intestinal Obstruction
14 drugs (12 approved, 2 experimental)
Intestinal Perforation
5 approved drugs
Intestinal Polyposis
7 approved drugs
Malabsorption Syndromes
28 drugs (12 approved, 16 experimental)
Mesenteric Ischemia
1 approved drug
Pneumatosis Cystoides Intestinalis
2 experimental drugs
Protein-Losing Enteropathies
5 drugs (3 approved, 2 experimental)
Rectal Diseases
9 drugs (6 approved, 3 experimental)
Zollinger-Ellison Syndrome
15 drugs (12 approved, 3 experimental)
Phase 4 Indicated Drugs (25)
Phase 3 Indicated Drugs (28)
Phase 2 Indicated Drugs (29)
Phase 1 Indicated Drugs (5)
Other Experimental Indicated Drugs (18)
Organization Involved with Phase 4 Indications (50)
Asociación Civil Selva Amazónica
Australasian Gastro Intestinal Research Foundation (AGIRF)
Canadian Institutes of Health Research (CIHR)
European Crohn´s and Colitis Organisation
Federal University of Juiz de Fora
Foundation for liver and gut studies
Organization Involved with Phase 3 Indications (58)
Autonomous University of Madrid
Bill and Melinda Gates Foundation
Centers for Disease Control and Prevention (CDC)
Chinese University of Hong Kong
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (GETAID)
Institut National de la Santé Et de la Recherche Médicale, France
International Center for Diarrheal Disease Research
Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Organization Involved with Phase 2 Indications (52)
Icahn School of Medicine at Mount Sinai
Istituto Clinico Humanitas - Rozzano (MI), Italy
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Organization Involved with Other Experimental Indications (40)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
